Li Yang, Cao Yanze, Zheng Mingxin, Hu Jiaqi, Yan Wei, Liu Xiaoyu, Liao Aijun, Yang Wei, Li Jian, Wang Huihan
Haematology Department of Shengjing Hospital, China Medical University, Shenyang, China.
Neusoft Research Institute, Northeastern University, Shenyang, China.
Front Oncol. 2021 Dec 9;11:758502. doi: 10.3389/fonc.2021.758502. eCollection 2021.
Light chain amyloidosis (AL) with cardiac involvement is associated with poor prognosis. The existing prognostic assessment system does not consider treatment-related factors, and there is currently no effective system for predicting the response. The purpose of this study was to build an individualized, dynamic assessment model for cardiac response and overall survival (OS) for AL patients with cardiac involvement.
The records of 737 AL patients with cardiac involvement were collected through cooperation with 18 hospitals in the Chinese Registration Network for Light-chain Amyloidosis (CRENLA). We used univariate and multivariate analyses to evaluate the prognostic factors for OS and cardiac response. Then, two nomogram models were developed to predict OS and cardiac response in AL patients with cardiac involvement.
A nomogram including four independent factors from the multivariate Cox proportional hazards analysis-Mayo staging, courses of treatment, hematologic response, and cardiac response-was constructed to calculate the possibility of achieving survival by adding all the points associated with four variables. The higher the score, the more likely death would occur. The other nomogram model included the courses of treatment, hematological response, and different treatment regimens, and was correlated with cardiac response. The higher the score, the more likely a cardiac response would occur.
In conclusion, based on the large Chinese cohort of patients with AL and cardiac involvement, we identified nomogram models to predict cardiac response and OS. These models are more individualized and dynamic, and therefore, they have important clinical application value.
心脏受累的轻链淀粉样变性(AL)与预后不良相关。现有的预后评估系统未考虑治疗相关因素,目前尚无有效的反应预测系统。本研究的目的是为心脏受累的AL患者建立一个针对心脏反应和总生存期(OS)的个体化动态评估模型。
通过与中国轻链淀粉样变性注册网络(CRENLA)的18家医院合作,收集了737例心脏受累的AL患者的记录。我们采用单因素和多因素分析来评估OS和心脏反应的预后因素。然后,开发了两个列线图模型来预测心脏受累的AL患者的OS和心脏反应。
构建了一个列线图,该列线图包含多因素Cox比例风险分析中的四个独立因素——梅奥分期、治疗疗程、血液学反应和心脏反应,通过将与四个变量相关的所有点数相加来计算生存可能性。分数越高,死亡可能性越大。另一个列线图模型包括治疗疗程、血液学反应和不同治疗方案,与心脏反应相关。分数越高,发生心脏反应的可能性越大。
总之,基于中国大量心脏受累的AL患者队列,我们确定了预测心脏反应和OS的列线图模型。这些模型更具个体化和动态性,因此具有重要的临床应用价值。